Solid Tumor
Conditions
Keywords
Norcantharidin Lipid Microsphere For Injection, Pharmacokinetics, Safety, Tolerance
Brief summary
This study was designed as a single-center, open, non-randomized trial.
Detailed description
In this study, patients with locally advanced or metastatic solid tumors were enrolled for a tolerance test and a pharmacokinetic study. The dosage increment principle of 3+3 was adopted. At the end of the tolerance test, 3 dose groups (low, medium and high) were selected to conduct pharmacokinetic studies after evaluation by the researchers on the premise of good safety, and at least 8 patients were included in each group for PK study (at least 8 patients in each group could be evaluated for PK ). After the end of the experimental drug tolerance and pharmacokinetics study, the safety and pharmacokinetics of single dose administration were compared with that of sodium norcantharidate for injection in the dose range of clinical use.
Interventions
DRUGNorcantharidin Lipid Microsphere for Injection
The test drug was added to 5% glucose injection to a final volume of 250 mL，and administered by instillation at a rate of 200 mL/h. This product can be used alone or in combination with chemotherapy, and the dosage and time of administration vary with the chemotherapy regimen.
DRUGSodium Demethylcantharidate Injection
Dissolve the reference drug with appropriate amount of sterile water for injection, and add 250 mL of 5% glucose injection for slow dripping.
Sponsors
Beijing Nuokangda Pharmaceutical Technology Co., Ltd.
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Single center, open, non-randomized trial design
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. Age 18-70 years old, regardless of gender. 2. Condition body mass index (BMI) = Weight (kg)/Height 2 (m2), the body mass index is in the range of 18-28 (Including the cut-off value). 3. Patients with locally advanced or metastatic solid tumors that have been clearly diagnosed by histology/cytology, patients whose condition is stable after standard treatment, or those who have failed standard treatment. 4. According to the Eastern Cooperative Oncology Group (ECOG) score of 0 to 2, the estimated survival time is ≥ 3 months. 5. It has sufficient organ and bone marrow functions, defined as follows: 1. Blood routine: white blood cell count (WBC) ≥ 4.0 × 109/L; neutrophil count (NEUT) ≥ 1.5 × 109/L; platelet count (PLT) ≥ 100 × 109/L; hemoglobin concentration ≥ 9.0 g/ dL; 2. Liver function: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 times the upper limit of normal (ULN); for patients with liver cancer or liver metastases, ALT and AST ≤ 5 times ULN; Total bilirubin (TBIL) ≤ 1.5 × ULN; 3. Renal function: blood creatinine (CREA) ≤ 1.5 × ULN; 4. Heart function: LVEF ≥ 50%. 6. Those who have used chemotherapeutics in the past need to stop the drug for more than 4 weeks (mitomycin or nitrosourea, need to stop for more than 6 weeks); have received surgery, molecular targeted therapy, and anti-tumor indications with Chinese medicine Those who need treatment should end at least 4 weeks, and those who have received palliative radiotherapy need more than 4 weeks of treatment. 7. Any toxicity associated with previous anti-tumor treatments must have been restored to ≤ Grade 1 (except for hair loss). 8. During the study period and within 3 months after the end of the administration, subjects with fertility (whether male or female) must receive effective contraceptive measures. 9. With my consent and signed an informed consent form by myself or my legal representative.
Exclusion criteria
1. Suffer from any clinically significant cardiovascular and cerebrovascular diseases within 3 months before taking the trial drug, including but not limited to myocardial infarction, severe/unstable angina, coronary artery/peripheral artery bypass graft, congestive heart failure, Cerebrovascular accident (including transient ischemic attack). 2. There is NCI-CTCAE grade ≥ grade 2 arrhythmia, any grade of atrial fibrillation that is not controlled, or the ECG found at the time of screening that the QT interval (QTc) for two consecutive corrections\> 480ms. 3. Any drug that may prolong the QTc interval or induce torsade de pointes ventricular tachycardia is required within 14 days before the first use of the test drug or during treatment. 4. History of allergic diseases and severe drug allergy. 5. Patients with uncontrolled tumor brain metastases with clinical symptoms. 6. Patients with severe infections (including but not limited to progressive or active infections) (for example, intravenous infusion of antibiotics, antifungal or antiviral drugs, etc.). 7. Patients with severe medical diseases, such as cardiac dysfunction of grade II and above (NYHA standard), ischemic heart disease (such as myocardial infarction or angina), congestive heart failure and other cardiovascular diseases, poorly controlled diabetes (Fasting blood glucose ≥10mmol/L), poorly controlled hypertension (systolic blood pressure\>150mmHg and/or diastolic blood pressure\>100mmHg). 8. Those who have bleeding tendency or are receiving thrombolysis or anticoagulation therapy. 9. Active hepatitis (hepatitis B, hepatitis C) or known HIV infection. 10. Other systemic anti-tumor treatments may be accepted during the study period. 11. A clear history of neurological or mental disorders, including epilepsy or dementia. 12. Have bad habits such as drug and alcohol abuse. Alcoholism refers to drinking behaviors of 4 or more times within about 2 hours. One-time drinking refers to drinking 150ml of wine, 350ml of beer, or 50ml of 80% liquor (or equivalent to the alcohol content). 13. Women during pregnancy or lactation. 14. Those who have received other drug clinical research within 1 month before the study. 15. Other situations where the researcher thinks it is inappropriate to participate in this research.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| AUC 0-∞ | ±1 minute | Area under the curve from administration to extrapolation to infinity: AUC0-∞=AUC0-t+Ct/λz, Ct is the last measurable concentration, and λz is the elimination rate constant. |
| Cmax | ±1 minute | Obtain directly according to the measured data of blood drug concentration-time. |
| AUC 0-t | ±1 minute | The area under the curve from the time of administration to the lowest detectable blood concentration: calculated by the linear trapezoidal rule. |
Countries
China
Contacts
Primary ContactYunpeng Liu, Ph.D
Outcome results
None listed